-
Breast cancer survivors suffering from lymphedema: What really do affect to corporeality/body image? A qualitative study Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-14 Laura González-Fernández, Carlos Romero-Morales, Beatriz Martínez-Pascual, Angela Río-González, Ester Cerezo-Téllez, Inmaculada López-Martín
Breast cancer-related lymphedema is currently one of the most serious complications that most affect the quality of life of women undergoing breast cancer. The aim of this study was to explore in-depth the experience of women who suffer from lymphoedema after breast cancer and how does this condition affect corporeality, with no judgements. For this purpose, a qualitative methodology was followed.
-
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-13 Rebecca A. Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B. Schwab, Emily I. Pittman, Minya Pu, Elizabeth Weihe, Emanuela M. Ghia, Laura Z. Rassenti, Alfredo Molinolo, Betty Cabrera, James B. Breitmeyer, George F. Widhopf II, Karen Messer, Catriona Jamieson, Thomas J. Kipps, Barbara A. Parker
Correction to: Shatsky et al. Breast Cancer Research (2024) 26:32https://doi.org/10.1186/s13058-024-01782-0 The original article contained three typesetting errors. “Her2-negative” in the title should have been written as “HER2-negative”. Hence, the title should read: A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast
-
Breast composition during and after puberty: the Chilean Growth and Obesity Cohort Study Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-12 Ana Pereira, María Luisa Garmendia, Valeria Leiva, Camila Corvalán, Karin B. Michels, John Shepherd
Breast density (BD) is a strong risk factor for breast cancer. Little is known about how BD develops during puberty. Understanding BD trajectories during puberty and its determinants could be crucial for promoting preventive actions against breast cancer (BC) at early ages. The objective of this research is to characterize % fibroglandular volume (%FGV), absolute fibroglandular volume (AFGV), and breast
-
UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5 Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-11 Juan Li, Yu Liang, Shijie Zhou, Jie Chen, Chihua Wu
Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) is a deubiquitinating enzyme that regulates ERα expression in triple-negative cancer (TNBC). This study aimed to explore the deubiquitination substrates of UCHL1 related to endocrine therapeutic responses and the mechanisms of UCHL1 dysregulation in TNBC. Bioinformatics analysis was conducted using online open databases. TNBC representative MDA-MB-468
-
Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-11 Sydney J. Conner, Justinne R. Guarin, Thanh T. Le, Jackson P. Fatherree, Charlotte Kelley, Samantha L. Payne, Savannah R. Parker, Hanan Bloomer, Crystal Zhang, Kenneth Salhany, Rachel A. McGinn, Emily Henrich, Anna Yui, Deepti Srinivasan, Hannah Borges, Madeleine J. Oudin
Metastasis is the leading cause of death in breast cancer patients. For metastasis to occur, tumor cells must invade locally, intravasate, and colonize distant tissues and organs, all steps that require tumor cell migration. The majority of studies on invasion and metastasis rely on human breast cancer cell lines. While it is known that these cells have different properties and abilities for growth
-
The role of surgical tissue injury and intraoperative sympathetic activation in postoperative immunosuppression after breast-conserving surgery versus mastectomy: a prospective observational study Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-11 Lotte MC Jacobs, Leonie S Helder, Kim I Albers, Josephine Kranendonk, Christiaan Keijzer, Leo AB Joosten, Luc JA Strobbe, Michiel C Warlé
Breast cancer is the second most common cause of death from cancer in women worldwide. Counterintuitively, large population-based retrospective trials report better survival after breast-conserving surgery (BCS) compared to mastectomy, corrected for tumour- and patient variables. More extensive surgical tissue injury and activation of the sympathetic nervous system by nociceptive stimuli are associated
-
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected? Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-11 Ximena Baez-Navarro, Nadine S. van den Ende, Anh H. Nguyen, Renata Sinke, Pieter Westenend, Johannes Bastiaan van Brakel, Claudia Stobbe, Johan Westerga, Carolien H. M. van Deurzen
Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results in TNBC, due to its immunogenicity. In addition, a novel antibody–drug conjugate, namely, trastuzumab-deruxtecan, has shown effectiveness in TNBC patients with low-HER2 expression (HER2-low)
-
Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-08 Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao
99mTc radiolabeled nanobody NM-02 (99mTc-NM-02) is a novel single photon emission computed tomography (SPECT) probe with a high affinity and specificity for human epidermal growth factor receptor 2 (HER2). In this study, a clinical imaging trial was conducted to investigate the relationship between 99mTc-NM-02 uptake and HER2 expression in patients with breast cancer. Thirty patients with pathologically
-
How does weight gain since the age of 18 years affect breast cancer risk in later life? A meta-analysis Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-07 Yunan Han, Ebunoluwa E. Otegbeye, Carrie Stoll, Angela Hardi, Graham A. Colditz, Adetunji T. Toriola
Early life factors are important risk factors for breast cancer. The association between weight gain after age 18 and breast cancer risk is inconsistent across previous epidemiologic studies. To evaluate this association, we conducted a meta-analysis according to PRISMA guidelines and the established inclusion criteria. We performed a comprehensive literature search using Medline (Ovid), Embase, Scopus
-
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-07 Miguel Castresana-Aguirre, Annelie Johansson, Alexios Matikas, Theodoros Foukakis, Linda S. Lindström, Nicholas P. Tobin
The clinical utility of gene signatures in older breast cancer patients remains unclear. We aimed to determine signature prognostic capacity in this patient subgroup. Research versions of the genomic grade index (GGI), 70-gene, recurrence score (RS), cell cycle score (CCS), PAM50 risk-of-recurrence proliferation (ROR-P), and PAM50 signatures were applied to 39 breast cancer datasets (N = 9583). After
-
The FBXW7-binding sites on FAM83D are potential targets for cancer therapy Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-07 Xiaoyu Jiang, Yuli Wang, Lulu Guo, Yige Wang, Tianshu Miao, Lijuan Ma, Qin Wei, Xiaoyan Lin, Jian-Hua Mao, Pengju Zhang
Increasing evidence shows the oncogenic function of FAM83D in human cancer, but how FAM83D exerts its oncogenic function remains largely unclear. Here, we investigated the importance of FAM83D/FBXW7 interaction in breast cancer (BC). We systematically mapped the FBXW7-binding sites on FAM83D through a comprehensive mutational analysis together with co-immunoprecipitation assay. Mutations at the FBXW7-binding
-
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-04 Jordi Rodón, David Demanse, Hope S. Rugo, Howard A. Burris, Rafael Simó, Azeez Farooki, Melissa F. Wellons, Fabrice André, Huilin Hu, Dragica Vuina, Cornelia Quadt, Dejan Juric
Hyperglycemia is an on-target effect of PI3Kα inhibitors. Early identification and intervention of treatment-induced hyperglycemia is important for improving management of patients receiving a PI3Kα inhibitor like alpelisib. Here, we characterize incidence of grade 3/4 alpelisib-related hyperglycemia, along with time to event, management, and outcomes using a machine learning model. Data for the risk
-
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-01 Stephen G. Smoots, Anna R. Schreiber, Marilyn M. Jackson, Stacey M. Bagby, Adrian T A. Dominguez, Evan D. Dus, Cameron A. Binns, Morgan MacBeth, Phaedra A. Whitty, Jennifer R. Diamond, Todd M. Pitts
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDAC) inhibitor that promotes apoptosis in TNBC preclinical models. The purpose of this study was to investigate
-
PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-26 Courtney M. Edwards, Jeremy F. Kane, Jailyn A. Smith, Déja M. Grant, Jasmine A. Johnson, Maria A. Hernandez Diaz, Lawrence A. Vecchi, Kai M. Bracey, Tolu N. Omokehinde, Joseph R. Fontana, Breelyn A. Karno, Halee T. Scott, Carolina J. Vogel, Jonathan W. Lowery, T. John Martin, Rachelle W. Johnson
The role of parathyroid hormone (PTH)-related protein (PTHrP) in breast cancer remains controversial, with reports of PTHrP inhibiting or promoting primary tumor growth in preclinical studies. Here, we provide insight into these conflicting findings by assessing the role of specific biological domains of PTHrP in tumor progression through stable expression of PTHrP (-36-139aa) or truncated forms with
-
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-26 Ting Song, Hong Zhang, Qicheng Zhao, Zhiyuan Hu, Ziqian Wang, Yang Song, Zhichao Zhang
Estrogen receptor (ER) positive patients compromise about 70% of breast cancers. Tamoxifen, an antagonist of ERα66 (the classic ER), is the most effective and the standard first-line drug. However, its efficacy is limited by the development of acquired resistance. A specific inhibitor of Hsp70-Bim protein–protein interaction (PPI), S1g-2, together with an inhibitor of Hsp70-Bag3 PPI, MKT-077 and an
-
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-26 Rebecca A. Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B. Schwab, Emily I. Pittman, Minya Pu, Elizabeth Weihe, Emanuela M. Ghia, Laura Z. Rassenti, Alfredo Molinolo, Betty Cabrera, James B. Breitmeyer, George F. Widhopf, Karen Messer, Catriona Jamieson, Thomas J. Kipps, Barbara A. Parker
Zilovertamab is a humanized monoclonal antibody targeting ROR1, an onco-embryonic antigen expressed by malignant cells of a variety of solid tumors, including breast cancer. A prior phase 1 study showed that zilovertamab was well tolerated and effective in inhibiting ROR1-signaling, which leads to activation of ERK1/2, NF-κB, and NRF2 target genes. This phase 1b study evaluated the safety and tolerability
-
Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-23 Minsun Jung, Seung Geun Song, Soo Ick Cho, Sangwon Shin, Taebum Lee, Wonkyung Jung, Hajin Lee, Jiyoung Park, Sanghoon Song, Gahee Park, Heon Song, Seonwook Park, Jinhee Lee, Mingu Kang, Jongchan Park, Sergio Pereira, Donggeun Yoo, Keunhyung Chung, Siraj M. Ali, So-Woon Kim
Accurate classification of breast cancer molecular subtypes is crucial in determining treatment strategies and predicting clinical outcomes. This classification largely depends on the assessment of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) status. However, variability in interpretation among pathologists pose challenges to the accuracy of
-
The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-20 Amelie Heesch, Alexandru Florea, Jochen Maurer, Pardes Habib, Laura S. Werth, Thomas Hansen, Elmar Stickeler, Sabri E. M. Sahnoun, Felix M. Mottaghy, Agnieszka Morgenroth
Overexpression of prostate-specific membrane antigen (PSMA) on the vasculature of triple-negative breast cancer (TNBC) presents a promising avenue for targeted endogenous radiotherapy with [177Lu]Lu-PSMA-I&T. This study aimed to assess and compare the therapeutic efficacy of a single dose with a fractionated dose of [177Lu]Lu-PSMA-I&T in an orthotopic model of TNBC. Rj:NMRI-Foxn1nu/nu mice were used
-
Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-19 Françoise Derouane, Manon Desgres, Camilla Moroni, Jérôme Ambroise, Martine Berlière, Mieke R. Van Bockstal, Christine Galant, Cédric van Marcke, Marianela Vara-Messler, Stefan J. Hutten, Jos Jonkers, Larissa Mourao, Colinda L. G. J. Scheele, Francois P. Duhoux, Cyril Corbet
Neoadjuvant chemotherapy (NAC) is the standard of care for patients with early-stage triple negative breast cancers (TNBC). However, more than half of TNBC patients do not achieve a pathological complete response (pCR) after NAC, and residual cancer burden (RCB) is associated with dismal long-term prognosis. Understanding the mechanisms underlying differential treatment outcomes is therefore critical
-
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-15 Claire Scheffges, Jérôme Devy, Jérôme Giustiniani, Stessy Francois, Lucille Cartier, Yacine Merrouche, Arnaud Foussat, Stéphane Potteaux, Armand Bensussan, Anne Marie-Cardine
Despite major therapeutic advances, triple-negative breast cancer (TNBC) still presents a worth prognosis than hormone receptors-positive breast cancers. One major issue relies in the molecular and mutational heterogeneity of TNBC subtypes that is reinforced by the absence of reliable tumor-antigen that could serve as a specific target to further promote efficient tumor cell recognition and depletion
-
Contrast-enhanced ultrasound to predict malignant upgrading of atypical ductal hyperplasia Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-12 Jun Kang Li, Zhi Ying Jin, Yong Jie Xu, Nai Qin Fu, Ying Jiang, Shi Yu Li, Rui Lan Niu, Gang Liu, Zhi Li Wang
A malignancy might be found at surgery in cases of atypical ductal hyperplasia (ADH) diagnosed via US-guided core needle biopsy (CNB). The objective of this study was to investigate the diagnostic performance of contrast-enhanced ultrasound (CEUS) in predicting ADH diagnosed by US-guided CNB that was upgraded to malignancy after surgery. In this retrospective study, 110 CNB-diagnosed ADH lesions in
-
MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-12 Mengfan Wang, Siyao Du, Si Gao, Ruimeng Zhao, Shasha Liu, Wenhong Jiang, Can Peng, Ruimei Chai, Lina Zhang
MRI-based tumor shrinkage patterns (TSP) after neoadjuvant therapy (NAT) have been associated with pathological response. However, the understanding of TSP after early NAT remains limited. We aimed to analyze the relationship between TSP after early NAT and pathological response after therapy in different molecular subtypes. We prospectively enrolled participants with invasive ductal breast cancers
-
Are better AI algorithms for breast cancer detection also better at predicting risk? A paired case–control study Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-07 Ruggiero Santeramo, Celeste Damiani, Jiefei Wei, Giovanni Montana, Adam R. Brentnall
There is increasing evidence that artificial intelligence (AI) breast cancer risk evaluation tools using digital mammograms are highly informative for 1–6 years following a negative screening examination. We hypothesized that algorithms that have previously been shown to work well for cancer detection will also work well for risk assessment and that performance of algorithms for detection and risk
-
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-07 Caroline Rönnlund, Emmanouil G. Sifakis, Caroline Schagerholm, Qiao Yang, Emelie Karlsson, Xinsong Chen, Theodoros Foukakis, Jodi Weidler, Michael Bates, Irma Fredriksson, Stephanie Robertson, Johan Hartman
Overexpression of human epidermal growth factor receptor 2 (HER2) caused by HER2 gene amplification is a driver in breast cancer tumorigenesis. We aimed to investigate the prognostic significance of manual scoring and digital image analysis (DIA) algorithm assessment of HER2 copy numbers and HER2/CEP17 ratios, along with ERBB2 mRNA levels among early-stage HER2-positive breast cancer patients treated
-
The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-05 Jing Qian, Yanxia Ma, William M. Tahaney, Cassandra L. Moyer, Amanda Lanier, Jamal Hill, Darian Coleman, Negar Koupaei, Susan G. Hilsenbeck, Michelle I. Savage, Brent D. G. Page, Abhijit Mazumdar, Powel H. Brown
The most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR), and does not have overexpression of the human epidermal growth factor receptor 2 (HER2). Treatment options for women with TNBC tumors are limited, unlike those with ER-positive tumors that can be treated with hormone therapy, or those
-
Low-dose acetylsalicylic acid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-05 Peter Lundberg, Annelie Abrahamsson, Johan Kihlberg, Jens Tellman, Ieva Tomkeviciene, Anette Karlsson, Maria Kristoffersen Wiberg, Marcel Warntjes, Charlotta Dabrosin
One major risk factor for breast cancer is high mammographic density. It has been estimated that dense breast tissue contributes to ~ 30% of all breast cancer. Prevention targeting dense breast tissue has the potential to improve breast cancer mortality and morbidity. Anti-estrogens, which may be associated with severe side-effects, can be used for prevention of breast cancer in women with high risk
-
Improving lesion detection in mammograms by leveraging a Cycle-GAN-based lesion remover Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-01 Juhun Lee, Robert M. Nishikawa
The wide heterogeneity in the appearance of breast lesions and normal breast structures can confuse computerized detection algorithms. Our purpose was therefore to develop a Lesion Highlighter (LH) that can improve the performance of computer-aided detection algorithms for detecting breast cancer on screening mammograms. We hypothesized that a Cycle-GAN based Lesion Remover (LR) could act as an LH
-
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-31 Filipa Lynce, Laura E. Stevens, Zheqi Li, Jane E. Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M. Force, Tufia C. Haddad, Naoto Ueno, Vered Stearns, Antonio C. Wolff, Amy S. Clark, Jennifer R. Bellon, Edward T. Richardson, Justin M. Balko, Ian E. Krop, Eric P. Winer, Paulina Lange, E. Shelley Hwang, Tari A. King, Sara M. Tolaney, Alastair Thompson, Gaorav P. Gupta, Elizabeth
Patients with inflammatory breast cancer (IBC) have overall poor clinical outcomes, with triple-negative IBC (TN-IBC) being associated with the worst survival, warranting the investigation of novel therapies. Preclinical studies implied that ruxolitinib (RUX), a JAK1/2 inhibitor, may be an effective therapy for TN-IBC. We conducted a randomized phase II study with nested window-of-opportunity in TN-IBC
-
ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-29 Jiahui Nie, Suying Dang, Rui Zhu, Tiantian Lu, Wei Zhang
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for about 20% of all breast cancer cases and is correlated with a high relapse rate and poor prognosis. ADAMTS18 is proposed as an important functional tumor suppressor gene involved in multiple malignancies, including breast cancer. It functions as an extracellular matrix (ECM) modifier. However, it remains unclear whether
-
Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-29 Xiaorui Han, Yuan Guo, Huifen Ye, Zhihong Chen, Qingru Hu, Xinhua Wei, Zaiyi Liu, Changhong Liang
Since breast cancer patients respond diversely to immunotherapy, there is an urgent need to explore novel biomarkers to precisely predict clinical responses and enhance therapeutic efficacy. The purpose of our present research was to construct and independently validate a biomarker of tumor microenvironment (TME) phenotypes via a machine learning-based radiomics way. The interrelationship between the
-
Development and prognostic validation of a three-level NHG-like deep learning-based model for histological grading of breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-29 Abhinav Sharma, Philippe Weitz, Yinxi Wang, Bojing Liu, Johan Vallon-Christersson, Johan Hartman, Mattias Rantalainen
Histological grade is a well-known prognostic factor that is routinely assessed in breast tumours. However, manual assessment of Nottingham Histological Grade (NHG) has high inter-assessor and inter-laboratory variability, causing uncertainty in grade assignments. To address this challenge, we developed and validated a three-level NHG-like deep learning-based histological grade model (predGrade). The
-
A genome-wide association study of contralateral breast cancer in the Women’s Environmental Cancer and Radiation Epidemiology Study Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-23 Xiaohui Sun, Anne S. Reiner, Anh Phong Tran, Gordon P. Watt, Jung Hun Oh, Lene Mellemkjær, Charles F. Lynch, Julia A. Knight, Esther M. John, Kathleen E. Malone, Xiaolin Liang, Meghan Woods, Andriy Derkach, Patrick Concannon, Jonine L. Bernstein, Xiang Shu
Contralateral breast cancer (CBC) is the most common second primary cancer diagnosed in breast cancer survivors, yet the understanding of the genetic susceptibility of CBC, particularly with respect to common variants, remains incomplete. This study aimed to investigate the genetic basis of CBC to better understand this malignancy. We performed a genome-wide association analysis in the Women’s Environmental
-
Differential patterns of reproductive and lifestyle risk factors for breast cancer according to birth cohorts among women in China, Japan and Korea Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-22 Salma Nabila, Ji-Yeob Choi, Sarah Krull Abe, Md Rashedul Islam, Md Shafiur Rahman, Eiko Saito, Aesun Shin, Melissa A. Merritt, Ryoko Katagiri, Xiao-Ou Shu, Norie Sawada, Akiko Tamakoshi, Ritsu Sakata, Atsushi Hozawa, Jeongseon Kim, Chisato Nagata, Sue K. Park, Sun-Seog Kweon, Hui Cai, Shoichiro Tsugane, Takashi Kimura, Seiki Kanemura, Yumi Sugawara, Keiko Wada, Min-Ho Shin, Habibul Ahsan, Paolo Boffetta
The birth cohort effect has been suggested to influence the rate of breast cancer incidence and the trends of associated reproductive and lifestyle factors. We conducted a cohort study to determine whether a differential pattern of associations exists between certain factors and breast cancer risk based on birth cohorts. This was a cohort study using pooled data from 12 cohort studies. We analysed
-
Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-22 Eunhye Kang, Ji-Jung Jung, Changjin Lim, Hong-Kyu Kim, Han-Byoel Lee, Wonshik Han, Hyeong-Gon Moon
This study aimed to investigate the contralateral breast cancer (CBC) recurrence rate in Korean breast cancer patients according to their BRCA1/2 germline mutation status, focusing particularly on the CBC recurrence risk in BRCA1/2 negative (BRCAx) patients. We conducted a retrospective study on 13,107 primary breast cancer patients. The patients were divided into high-risk and low-risk groups for
-
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-18 Jieun Park, Eun Sol Chang, Ji-Yeon Kim, Chaithanya Chelakkot, Minjung Sung, Ji-Young Song, Kyungsoo Jung, Ji Hye Lee, Jun Young Choi, Na Young Kim, Hyegyeong Lee, Mi-Ran Kang, Mi Jeong Kwon, Young Kee Shin, Yeon Hee Park, Yoon-La Choi
Endocrine therapy resistance in hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer (BC) is a significant clinical challenge that poses several unmet needs in the management of the disease. This study aimed to investigate the prognostic value of c-MET-positive circulating tumor cells (cMET+ CTCs), ESR1/PIK3CA mutations, and cell-free DNA (cfDNA) concentrations in patients with hormone
-
Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-18 Timothy B. Fisher, Geetanjali Saini, T. S. Rekha, Jayashree Krishnamurthy, Shristi Bhattarai, Grace Callagy, Mark Webber, Emiel A. M. Janssen, Jun Kong, Ritu Aneja
Pathological complete response (pCR) is associated with favorable prognosis in patients with triple-negative breast cancer (TNBC). However, only 30–40% of TNBC patients treated with neoadjuvant chemotherapy (NAC) show pCR, while the remaining 60–70% show residual disease (RD). The role of the tumor microenvironment in NAC response in patients with TNBC remains unclear. In this study, we developed a
-
Evidence of steady-state fibroblast subtypes in the normal human breast as cells-of-origin for perturbed-state fibroblasts in breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-16 Mikkel Morsing Bagger, Jonas Sjölund, Jiyoung Kim, Katharina Theresa Kohler, René Villadsen, Abbas Jafari, Moustapha Kassem, Kristian Pietras, Lone Rønnov-Jessen, Ole William Petersen
Human breast cancer most frequently originates within a well-defined anatomical structure referred to as the terminal duct lobular unit (TDLU). This structure is endowed with its very own lobular fibroblasts representing one out of two steady-state fibroblast subtypes—the other being interlobular fibroblasts. While cancer-associated fibroblasts (CAFs) are increasingly appreciated as covering a spectrum
-
PFKP deubiquitination and stabilization by USP5 activate aerobic glycolysis to promote triple-negative breast cancer progression Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-12 Zi-Mei Peng, Xiao-Jian Han, Tao Wang, Jian-Jun Li, Chun-Xi Yang, Fang-Fang Tou, Zhen Zhang
Triple-negative breast cancer (TNBC) remains the most challenging subtype of breast cancer and lacks definite treatment targets. Aerobic glycolysis is a hallmark of metabolic reprogramming that contributes to cancer progression. PFKP is a rate-limiting enzyme involved in aerobic glycolysis, which is overexpressed in various types of cancers. However, the underlying mechanisms and roles of the posttranslational
-
Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-11 Nianhua Ding, Jian Pang, Xuan Liu, Xiongbin He, Wei Zhou, Haiqing Xie, Jianqi Feng, Guo Wang, Jie Tang, Jing Cao, Liying He, Yingjian He, Shouman Wang, Zhi Xiao
This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab. Data from 780 patients from the CLEOPATRA trial and 248 local patients were collected. Patients were divided into the low and high NLR subgroups by the NLR cutoff value. Propensity score matching (PSM) and inverse
-
Risk-management decision-making data from a community-based sample of racially diverse women at high risk of breast cancer: rationale, methods, and sample characteristics of the Daughter Sister Mother Project survey Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-11 Tasleem J. Padamsee, Christina Bijou, Paige Swinehart-Hord, Megan Hils, Anna Muraveva, Rachel J. Meadows, Kate Shane-Carson, Lisa D. Yee, Celia E. Wills, Electra D. Paskett
To understand the dynamics that limit use of risk-management options by women at high risk of breast cancer, there is a critical need for research that focuses on patient perspectives. Prior research has left important gaps: exclusion of high-risk women not in risk-related clinical care, exclusion of non-white populations, and lack of attention to the decision-making processes that underlie risk-management
-
Machine learning prediction of pathological complete response and overall survival of breast cancer patients in an underserved inner-city population Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-10 Kevin Dell’Aquila, Abhinav Vadlamani, Takouhie Maldjian, Susan Fineberg, Anna Eligulashvili, Julie Chung, Richard Adam, Laura Hodges, Wei Hou, Della Makower, Tim Q. Duong
Generalizability of predictive models for pathological complete response (pCR) and overall survival (OS) in breast cancer patients requires diverse datasets. This study employed four machine learning models to predict pCR and OS up to 7.5 years using data from a diverse and underserved inner-city population. Demographics, staging, tumor subtypes, income, insurance status, and data from radiology reports
-
Male with an apparently normal phenotype carrying a BRCA1 exon 20 duplication in trans to a BRCA1 frameshift variant Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-09 Ines Block, Àngels Mateu-Regué, Thi Tuyet Nhu Do, Ieva Miceikaite, Daniel Sdogati, Martin J. Larsen, Qin Hao, Henriette Roed Nielsen, Susanne E. Boonen, Anne-Bine Skytte, Uffe Birk Jensen, Louise K. Høffding, Arcangela De Nicolo, Alessandra Viel, Emma Tudini, Michael T. Parsons, Thomas V. O. Hansen, Maria Rossing, Torben A. Kruse, Amanda B. Spurdle, Mads Thomassen
Reports of dual carriers of pathogenic BRCA1 variants in trans are extremely rare, and so far, most individuals have been associated with a Fanconi Anemia-like phenotype. We identified two families with a BRCA1 in-frame exon 20 duplication (Ex20dup). In one male individual, the variant was in trans with the BRCA1 frameshift variant c.2475delC p.(Asp825Glufs*21). We performed splicing analysis and used
-
Targeting tumor–stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-05 Stephanie J. Hachey, Christopher J. Hatch, Daniela Gaebler, Aneela Mocherla, Kevin Nee, Kai Kessenbrock, Christopher C. W. Hughes
Triple-negative breast cancer (TNBC) is highly aggressive with limited available treatments. Stromal cells in the tumor microenvironment (TME) are crucial in TNBC progression; however, understanding the molecular basis of stromal cell activation and tumor–stromal crosstalk in TNBC is limited. To investigate therapeutic targets in the TNBC stromal niche, we used an advanced human in vitro microphysiological
-
Identification of a Notch transcriptomic signature for breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-03 Eike-Benjamin Braune, Felix Geist, Xiaojia Tang, Krishna Kalari, Judy Boughey, Liewei Wang, Roberto A. Leon-Ferre, Antonino B. D’Assoro, James N. Ingle, Matthew P. Goetz, Julian Kreis, Kang Wang, Theodoros Foukakis, Anita Seshire, Dirk Wienke, Urban Lendahl
Dysregulated Notch signalling contributes to breast cancer development and progression, but validated tools to measure the level of Notch signalling in breast cancer subtypes and in response to systemic therapy are largely lacking. A transcriptomic signature of Notch signalling would be warranted, for example to monitor the effects of future Notch-targeting therapies and to learn whether altered Notch
-
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-03 Joanna I. López-Velazco, Sara Manzano, María Otaño, Kepa Elorriaga, Núria Bultó, Julio Herrero, Ainhara Lahuerta, Virginia Segur, Isabel Álvarez-López, Maria M. Caffarel, Ander Urruticoechea
Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive (ER+) /HER2-negative (HER2-) breast cancer allows real-time evaluation of drug efficacy as well as investigation of the biological and molecular changes that occur after estrogenic deprivation. Clinical and pathological evaluation after NET may be used to obtain prognostic and predictive information of tumour response to decide adjuvant
-
Addition of polygenic risk score to a risk calculator for prediction of breast cancer in US Black women Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-02 Gary R. Zirpoli, Ruth M. Pfeiffer, Kimberly A. Bertrand, Dezheng Huo, Kathryn L. Lunetta, Julie R. Palmer
Previous work in European ancestry populations has shown that adding a polygenic risk score (PRS) to breast cancer risk prediction models based on epidemiologic factors results in better discriminatory performance as measured by the AUC (area under the curve). Following publication of the first PRS to perform well in women of African ancestry (AA-PRS), we conducted an external validation of the AA-PRS
-
Protein disulfide isomerase family member 4 promotes triple-negative breast cancer tumorigenesis and radiotherapy resistance through JNK pathway Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-02 Jinqiu Tao, Cailin Xue, Meng Cao, Jiahui Ye, Yulu Sun, Hao Chen, Yinan Guan, Wenjie Zhang, Weijie Zhang, Yongzhong Yao
Despite radiotherapy ability to significantly improve treatment outcomes and survival in triple-negative breast cancer (TNBC) patients, acquired resistance to radiotherapy poses a serious clinical challenge. Protein disulfide isomerase exists in endoplasmic reticulum and plays an important role in promoting protein folding and post-translational modification. However, little is known about the role
-
Association between allostatic load and breast cancer risk: a cohort study Breast Cancer Res. (IF 7.4) Pub Date : 2023-12-19 Yufan Guan, Jie Shen, Juan Lu, Bernard F. Fuemmeler, Lisa S. Shock, Hua Zhao
Allostatic load (AL) reflects the collective load of chronic stress during lifetime. Previous studies have shown that higher AL is associated with poor clinical outcomes among breast cancer patients. However, the relationship between AL and breast cancer risk is still unclear. To fill the gap, we analyzed the association between AL and the development of breast cancer in 181,455 women identified from
-
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results Breast Cancer Res. (IF 7.4) Pub Date : 2023-12-14 Jeongmin Seo, Jiwon Koh, Dae-Won Lee, Jinyong Kim, Han Suk Ryu, Kyung-Hun Lee, Tae-Yong Kim, Seock-Ah Im
The role of HER2 amplification level in predicting the effectiveness of HER2-directed therapies has been established. However, its association with survival outcomes in advanced HER2-positive breast cancer treated with dual HER2-blockade remains unexplored. This is a single-center retrospective study of patients with advanced HER2-positive breast cancer treated with first-line pertuzumab, trastuzumab
-
Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials Breast Cancer Res. (IF 7.4) Pub Date : 2023-12-14 Davut Dayan, Stefan Lukac, Brigitte Rack, Florian Ebner, Visnja Fink, Elena Leinert, Kristina Veselinovic, Sabine Schütze, Ziad El Taie, Wolfgang Janni, Thomas W. P. Friedl
Invasive lobular breast carcinomas (ILC) have different histological features compared to non-special type carcinomas (NST), but the effect of histological subtypes on survival is controversial. In this study, we compared clinicopathological characteristics and outcomes between ILC and NST based on a large pooled data set from three adjuvant breast cancer trials (SUCCESS A, B, and C) and investigated
-
Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study Breast Cancer Res. (IF 7.4) Pub Date : 2023-12-14 Han-Fang Cheng, Yi-Fang Tsai, Chun-Yu Liu, Chih-Yi Hsu, Pei-Ju Lien, Yen-Shu Lin, Ta-Chung Chao, Jiun-I. Lai, Chin-Jung Feng, Yen-Jen Chen, Bo-Fang Chen, Jen-Hwey Chiu, Ling-Ming Tseng, Chi-Cheng Huang
The homologous recombination (HR) repair pathway for DNA damage, particularly the BRCA1 and BRCA2 genes, has become a target for cancer therapy, with poly ADP-ribose polymerase (PARP) inhibitors showing significant outcomes in treating germline BRCA1/2 (gBRCA1/2) mutated breast cancer. Recent studies suggest that some patients with somatic BRCA1/2 (sBRCA1/2) mutation or mutations in HR-related genes
-
Therapeutic protein PAK restrains the progression of triple negative breast cancer through degrading SREBP-1 mRNA Breast Cancer Res. (IF 7.4) Pub Date : 2023-12-11 Pan Hu, Peiyi Zhou, Tieyun Sun, Dingkang Liu, Jun Yin, Lubin Liu
Triple-negative breast cancer (TNBC) represents the most challenging subtype of breast cancer. Studies have implicated an upregulation of lipid synthesis pathways in the initiation and progression of TNBC. Targeting lipid synthesis pathways may be a promising therapeutic strategy for TNBC. Our previous study developed a therapeutic protein PAK with passive targeting and inhibiting tumor proliferation
-
Mosquito control exposures and breast cancer risk: analysis of 1071 cases and 2096 controls from the Ghana Breast Health Study Breast Cancer Res. (IF 7.4) Pub Date : 2023-12-11 Naomie Olivos, Jim E. Banta, Rhonda Spencer-Hwang, Daniel Ansong, Laura E. Beane Freeman, Joe-Nat Clegg-Lamptey, Beatrice Wiafe-Addai, Lawrence Edusei, Ernest Adjei, Nicholas Titiloye, Florence Dedey, Francis Aitpillah, Joseph Oppong, Verna Vanderpuye, Ernest Osei-Bonsu, Thomas U. Ahearn, Richard Biritwum, Joel Yarney, Baffour Awuah, Kofi Nyarko, Montserrat Garcia-Closas, Mustapha Abubakar, Louise
Epidemiologic data on insecticide exposures and breast cancer risk are inconclusive and mostly from high-income countries. Using data from 1071 invasive pathologically confirmed breast cancer cases and 2096 controls from the Ghana Breast Health Study conducted from 2013 to 2015, we investigated associations with mosquito control products to reduce the spread of mosquito-borne diseases, such as malaria
-
Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study Breast Cancer Res. (IF 7.4) Pub Date : 2023-12-08 Shih-Kai Hung, Hsuan-Ju Yang, Moon-Sing Lee, Dai-Wei Liu, Liang-Cheng Chen, Chia-Hui Chew, Chun-Hung Lin, Cheng-Hung Lee, Szu-Chin Li, Chung-Lin Hong, Chih-Chia Yu, Ben-Hui Yu, Feng-Chun Hsu, Wen-Yen Chiou, Hon-Yi Lin
Based on the molecular expression of cancer cells, molecular subtypes of breast cancer have been applied to classify patients for predicting clinical outcomes and prognosis. However, further evidence is needed regarding the influence of molecular subtypes on the efficacy of radiotherapy (RT) after breast-conserving surgery (BCS), particularly in a population-based context. Hence, the present study
-
Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2023-11-28 Zheqiong Tan, Pragney Deme, Keerti Boyapati, Britt S. R. Claes, Annet A. M. Duivenvoorden, Ron M. A. Heeren, Caitlin M. Tressler, Norman James Haughey, Kristine Glunde
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and leads to the poorest patient outcomes despite surgery and chemotherapy treatment. Exploring new molecular mechanisms of TNBC that could lead to the development of novel molecular targets are critically important for improving therapeutic options for treating TNBC. We sought to identify novel therapeutic targets in
-
Development and evaluation of a method to assess breast cancer risk using a longitudinal history of mammographic density: a cohort study Breast Cancer Res. (IF 7.4) Pub Date : 2023-11-24 Emma C. Atakpa, Diana S. M. Buist, Erin J. Aiello Bowles, Jack Cuzick, Adam R. Brentnall
Women with dense breasts have an increased risk of breast cancer. However, breast density is measured with variability, which may reduce the reliability and accuracy of its association with breast cancer risk. This is particularly relevant when visually assessing breast density due to variation in inter- and intra-reader assessments. To address this issue, we developed a longitudinal breast density
-
Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2023-11-22 Menekse Göker, Hannelore Denys, An Hendrix, Olivier De Wever, Koen Van de Vijver, Geert Braems
The aim of the study was to compare the difference in survival between invasive ductal (IDC) and lobular carcinoma (ILC). Data of patients (n = 1843) with a hormone receptor-positive, HER2-negative, pT1-3 IDC or ILC cancer without distant metastasis, treated at the Ghent University Hospital over the time period 2001–2015, were analyzed. ILC represented 13.9% of the tumors, had a higher percentage of
-
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2023-11-15 Noortje Verschoor, Marcel Smid, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W. M. Martens
In breast cancer, the advent of anti-HER2 therapies has made HER2+ tumors a highly relevant subgroup. However, the exact characteristics which prohibit clinical response to anti-HER2 therapies and drive disease progression are not yet fully known. Integrative whole-genome and transcriptomic sequencing data from both primary and metastatic HER2-positive breast cancer will enhance our understanding of
-
The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling Breast Cancer Res. (IF 7.4) Pub Date : 2023-11-15 Deeksha Sharma, Cody G. Hager, Li Shang, Lam Tran, Yongyou Zhu, Aihui Ma, Brian Magnuson, Matthew W. Lesko, Max S. Wicha, Monika L. Burness
Breast cancer stem cells (BCSCs) are resistant to standard therapies, facilitate tumor dissemination, and contribute to relapse and progression. Super-enhancers are regulators of stemness, and BET proteins, which are critical for super-enhancer function, are a potential therapeutic target. Here, we investigated the effects of BET proteins on the regulation of breast cancer stemness using the pan-BET
-
Formation of an invasion-permissive matrix requires TGFβ/SNAIL1-regulated alternative splicing of fibronectin Breast Cancer Res. (IF 7.4) Pub Date : 2023-11-14 Héctor Franco-Valls, Elsa Tusquets-Uxó, Laura Sala, Maria Val, Raúl Peña, Alessandra Iaconcig, Álvaro Villarino, Martín Jiménez-Arriola, Pere Massó, Juan L. Trincado, Eduardo Eyras, Andrés F. Muro, Jorge Otero, Antonio García de Herreros, Josep Baulida
As in most solid cancers, the emergence of cells with oncogenic mutations in the mammary epithelium alters the tissue homeostasis. Some soluble factors, such as TGFβ, potently modify the behavior of healthy stromal cells. A subpopulation of cancer-associated fibroblasts expressing a TGFβ target, the SNAIL1 transcription factor, display myofibroblastic abilities that rearrange the stromal architecture